Posts Tagged ‘Dry Eye’
Dry Eye Newbie Xiidra Grabs Large Market Share
During the run-up to the launch of Shire’s dry eye drug Xiidra (lifitegrast), it seemed as though everyone was wondering what kind of threat – if any – it would pose to Allergan’s Restasis (topical cyclosporine 0.05%). With an estimated 30 million dry eye sufferers and only 1 million or so on prescription treatment, many…
Read MoreAXIM Rolls Medical Marijuana Ball in Ophthalmology
Medical marijuana has quickly gained acceptance as a viable treatment for a variety of health conditions, such as the side effects of chemotherapy, the neurodegenerative effects of Alzheimer’s disease, certain seizures and chronic pain without the addictive effects of opioids. But in ophthalmology, medical marijuana has encountered the headwinds of controversy. The American Glaucoma Society…
Read MoreCan Lighting Strike Twice? SARCode’s Co-Founder Gadek Takes Helm of Promising Dry Eye Start-up
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 114″] Three-year-old TearSolutions hopes to pen a strong sequel to SARCode’s successful tale of a start-up developing the next new treatment for Dry Eye Disease. Tom Gadek, co-founder of SARCode, developer of lifitegrast (now Shire’s potential blockbuster Xiidra), takes over the company as it begins courting partners and investors. Transcript…
Read MoreShire’s Dempsey Shares Strategy to Building a Brand in Ophthalmology
Robert Dempsey, Vice President and Business Unit Head of Ophthalmology, Shire. See below for the Video Timestamp: 00:30 – How do you build a brand without a pipeline? 2:10 – Why did Shire choose to build in ophthalmology? 3:50 – Did Shire consider buying 5:15 – We are not dipping our toes in the water.…
Read MoreDempsey on Building the Shire Brand in Ophthalmology
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 087″] Robert Dempsey, vice president of ophthalmics at Shire, was charged with building a brand in ophthalmology with no new drugs. Two years later, Shire has – in the words of one physician – one of “the best kept secrets” in eye care. Dempsey explains how Shire came to build something…
Read MoreLacriScience Enters Next Chapter
Chris D. Geddes, Ph.D, and Paul Gavaris of LacriScience share the prototype of the LacriPen, a handheld, portable, diagnostic tool that measures osmolarity to within 2 mOsml and can detect other viruses and bacteria including Methicillin-resistant Staphylococcus aureus (MRSA). Highlights 00:24 – “This has been a pivotal moment.” 00:53 – “We’ve had a lot of traction…
Read MoreTearScience Pivots to Focus on Early-Stage OSD
TearScience, the device company focused on the role of the meibomian glands in dry eye, has pivoted its business model to concentrate more on early-stage meibomian gland dysfunction (MGD) with the LipiFlow thermal pulsation device and high-definition imaging of the meibomian glands, President and CEO Joseph Boorady, OD, told OIS@ASCRS 2016. Dr. Boorady himself is…
Read MoreTearLab Targets Multiple Biomarkers in Dry Eye
A physiologically stable ocular surface is a big determinant in cataract and refractive surgery outcomes, so TearLab Corp. is looking to build out its lab-on-a-chip platform to evaluate the ocular surface for additional biomarkers, CEO Seph Jensen told the panel on diagnostics and the premium channel at OIS@ASCRS 2016. The TearLab Osmolarity Test, for diagnosing…
Read MoreNew CEO Boorady Explains TearScience’s Strategic Shift
TearScience, the device company focused on the role of the meibomian glands in dry eye, has pivoted its business model to concentrate more on early-stage meibomian gland dysfunction (MGD) with the LipiFlow thermal pulsation device and high-definition imaging of the meibomian glands. Highlights 00:39 – When did you join TearScience and what changes did you…
Read MoreOISPodcast@ASCRS – Meury: Why Allergan Won’t Miss a Beat in Building Ophthalmology Franchise
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 086″] Deals sometime collapse, but they usually don’t get hit with a smart bomb from the Department of Treasury. Allergan, newly single following the break up with Pfizer, is looking to build a business in ophthalmology. Bill Meury, the newly named chief commercial officer of Allergan, talks about the non-Pfizer deal,…
Read MoreWithout Pfizer Deal, Allergan Looks Ahead: Could B+L be in its Sights?
Now that Pfizer and Allergan have mutually agreed to terminate their proposed merger, Allergan CEO Brent Saunders told analysts Wednesday morning that the company is moving ahead with new product development, but he would not rule out the possibility of Allergan making a play for his old employer, Bausch + Lomb. The merger foundered when…
Read More2016 Promises to Disrupt Dry Eye
This year promises to deliver disruption to the dry eye disease market as companies work to roll out new drugs, devices, and diagnostics. Shire may deliver the biggest success. The company is close to bringing a second therapeutic to the market to treat dry eye conditions, as lifitegrast is currently awaiting US regulatory approval. If…
Read More